A Cancer Research UK Phase I dose escalation trial of oral VEGFR and EGFR inhibitor, Vandetanib in combination with the oral MEK inhibitor, Selumetinib (VanSel-1) in solid tumours (dose escalation) and NSCLC (expansion cohort)

Trial Profile

A Cancer Research UK Phase I dose escalation trial of oral VEGFR and EGFR inhibitor, Vandetanib in combination with the oral MEK inhibitor, Selumetinib (VanSel-1) in solid tumours (dose escalation) and NSCLC (expansion cohort)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Selumetinib (Primary) ; Vandetanib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms VanSel1
  • Most Recent Events

    • 13 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top